Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct;30(5):293-301.
doi: 10.5114/pdia.2013.38358. Epub 2013 Oct 30.

Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development

Małgorzata Bondaryk  1 , Wiesław Kurzątkowski  1 , Monika Staniszewska  1
Affiliations
Review

Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development

Małgorzata Bondaryk et al. Postepy Dermatol Alergol. 2013 Oct.

Abstract

Recent progress in medical sciences and therapy resulted in an increased number of immunocompromised individuals. Candida albicans is the leading opportunistic fungal pathogen causing infections in humans, ranging from superficial mucosal lesions to disseminated or bloodstream candidiasis. Superficial candidiasis not always presents a risk to the life of the infected host, however it significantly lowers the quality of life. Superficial Candida infections are difficult to treat and their frequency of occurrence is currently rising. To implement successful treatment doctors should be up to date with better understanding of C. albicans resistance mechanisms. Despite high frequency of Candida infections there is a limited number of antimycotics available for therapy. This review focuses on current understanding of the mode of action and resistance mechanisms to conventional and emerging antifungal agents for treatment of superficial and mucosal candidiasis.

Keywords: Candida albicans; antifungal agents; mode of action; resistance mechanisms.

PubMed Disclaimer

References

    1. Kourkoumpetis T, Manolakaki D, Velmahos GC, et al. Candida infection and colonization among non-trauma emergency surgery patients. Virulence. 2010;1:359–66. - PubMed
    1. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev. 2003;67:400–28. - PMC - PubMed
    1. Pfaller MA, Diakema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–63. - PMC - PubMed
    1. Gropp K, Schild L, Schindler S, et al. The yeast Candida albicans evades human complement attack by secretion of aspartyl proteases. Mol Immunol. 2009;47:465–75. - PubMed
    1. Soll DR, Lockhart SR, Zhao R. Relationship between switching and mating in Candida albicans. Eukaryot Cell. 2002;2:390–7. - PMC - PubMed